Advances in B Lymphblastic Leukemia MRD. Brent Wood MD PhD Departments of Laboratory Medicine and Pathology University of Washington.
|
|
- Britton Allison
- 6 years ago
- Views:
Transcription
1 Advances in B Lymphblastic Leukemia MRD Brent Wood MD PhD Departments of Laboratory Medicine and Pathology University of Washington
2 Measures of Response Clinical outcome OS, EFS, RFS, etc. Blast count Remission = < 5% by morphology Minimal Residual Disease Cytogenetics, Flow, Molecular
3 Pediatric AML Blast count does not correlate with MRD Inaba, et al (2012) JCO 30:
4 Pediatric AML Blasts < 5% MRD- MRD+ Blasts 5% Morphologic blast count is not predictive Inaba, et al (2012) JCO 30:
5 AML Pre-Transplant MRD- Blasts < 5% Pre-Tx Blasts > 5% = MRD+ Blasts < 5% Araki, et al (2015) JCO (in press)
6 ALL Morphology vs. Flow 0.8% M1 but Flow > 5% 6.5% M1 but Flow > 5% Gupta, et al (2016) ASH 2016
7 ALL Morphology vs. Flow B-ALL T-ALL Gupta, et al (2016) ASH 2016
8 Need a new definition of remission Morphologic blast counts correlate poorly with response in AML Shouldn t use in clinical trial design Assess residual disease by other methods
9 Reproducibility
10 Sources of Variability Identification (false positive or negative) Insufficiently informative reagents Improper assay validation Immunophenotypic shift Inexperienced interpreters Quantitation Too few events acquired Denominator effects (2 fold) Sample degeneration Hemodilution
11 Borowitz, Wood, et al (2015) Blood 126(8):964-71
12 % of cases MRD >.01% Flow MRD on AALL03B d29 d15* d8 blood JHU(n=2282) UW(n=1947) * day 8 M1 patients excluded Unpublished data, courtesy Mike Borowitz
13 Day 29 Flow MRD on AALL0232 FIGURE S3 COMPARISON OF MRD RATES BETWEEN THE EASTERN AND WESTERN REFERENCE LABORATORIES % 0.1-1% >1% overall MRD level % of cases JHU (n=1204) UW (n=1228) Figure S3. Comparison of MRD Borowitz, rates between Wood, the et al two (2015) reference Blood laboratories. 126(8): The
14 Correlation between labs Borowitz, Wood, et al (2015) Blood 126(8):964-71
15 CCR probability Correlation between labs AALL % <= Day 29 MRD < 1.0% Eastern Region (n = 121) Western Region (n = 114) Years P = Borowitz, Wood, et al (2015) Blood 126(8):964-71
16 67% 67% 67% % Attempted 67% % Attempted 5 5 # Positive # Positive # Positive # Negative # Negative # Negative False POS False POS False POS False NEG False NEG False NEG % 87% 60% 60% 87% 80% 90% 60% 87% 90%(%) Concordance Overall 60% 90% 60% 90% 90% Log (log) % 90% 60% 90% 90% 60% 87% Interpretive Variability 26 60% 87% 70% 73% 53% 60% 80 70% Outside 0.5log 80Concordance 90%(%) Overall Concordance (%) Outside Log (log) 0.5log Concordance (%) Last 2 rounds.tc s. re First 3 rounds 90% 53% s. in Overall 87% Concordance (%) Outside Log (log) 0.5log 87% 73% Concordance (%) 87% FIGURE 2B: Dist the results from the rounds of sendouts reference laborat review of the first and educational se MRD analysis. w FIGURE 2A: Distribution of FIGURE 2A: Distribution of the 3results from the first 3 the results from the first of sendouts from rounds of sendouts rounds from the reference laboratorythe reference laboratory w %) Experience with MRD Testing in B- ALL By Flow Cytometry Does Not Prevent Interpretative Discordance w %) % Attempted Keeney, Wood et al. (2017) Cytometry B
17 Reproducibility Flow cytometry is capable of reproducible MRD detection and enumeration Lack of standardization in implementation is the source of variability in current practice
18 Opportunities
19 Anti-CD19 Immunotherapy Targets primary gating reagent Identifying B cells difficult Eliminates expression of CD19 Rapidly after administration Selects for CD19 (-) subset of leukemia CD19 (-) MRD and relapse Need alternate strategy CD22, CD24 + CD66b, ccd79a Now routine assay
20 CD24 APC CD10 BV421 CD38 A594 CD24 APC CD22 PE CD19 PE-Cy7 Anti-CD19 Immunotherapy Viable Viable CD66b FITC CD66b FITC CD10 PE B cells B cells B cells CD22 PE CD20 PE-Cy7 CD10 BV421 CD19-negative MRD with background hematogones B Cells HP Cherian, et al (2016) Clin Cyto Part B
21 MRD by Flow Cytometry Advantages Fast Relatively inexpensive Large instrument base Reproducible Disadvantages Subjective interpretation Immunophenotypic drift after therapy Moderate sensitivity Poorly standardized
22 V IgH and TCR Diversity 54 2 V D J V D RSS RSS RSS RSS N D N J 13 J
23 MRD by NGS Faham et al (2012) Blood 120:
24 Day 0 Cancer clone Frequency Day 29 Cancer clone Frequency PT_44 PT_63 PT_48 PT_9 PT_7 PT_15 PT_59 PT_36 PT_33 PT_53 PT_52 PT_5 PT_50 PT_1 PT_32 PT_8 PT_30 PT_49 PT_66 PT_39 PT_65 PT_41 PT_61 PT_51 PT_6 PT_47 PT_4 PT_58 PT_2 PT_40 PT_14 PT_55 PT_57 PT_3 PT_12 PT_54 PT_45 PT_60 PT_68 PT_56 PT_13 PT_42 PT_11 PT_44 PT_63 PT_48 PT_9 PT_7 PT_15 PT_59 PT_36 PT_33 PT_53 PT_52 PT_5 PT_50 PT_1 PT_32 PT_8 PT_30 PT_49 PT_66 PT_39 PT_65 PT_41 PT_61 PT_51 PT_6 PT_47 PT_4 PT_58 PT_2 PT_40 PT_14 PT_55 PT_57 PT_3 PT_12 PT_54 PT_45 PT_60 PT_68 PT_56 PT_13 PT_42 PT_11 Individual ETP netp Flow Cytometry TCRBSEQ Wu, et al (2012) Sci Trans Med 4: 1-7
25 93 / 98 (95%) with IgH rearrangement Remainder: 2 with D-J, 1 with clonal D-J + many VH, 2 none Wu, et al (2014) Clin Cancer Res 20:4540-8
26 MRD AND TRANSPLANT Flow vs NGS Pulsipher et al Blood 2014;123:2017 Pulsipher et al Blood 2015;125:3501 Better definition of low risk through higher sensitivity
27 NGS A SWOG 0333 C" D B" Flow Sala-Torra et al (2017) In Press
28 B-LL End of Induction MRD Flow and HTS are equivalent at 0.01% Use of cutoff < 0.01% does not improve risk stratification
29 B-LL End of Induction MRD Standard Risk High Risk Lower MRD more informative for high risk
30 B-LL End of Induction MRD Absence of detectable MRD by NGS = Excellent outcome Standard risk patients
31 B-LL End of Induction MRD Absence of detectable MRD by NGS for High risk patients Standard risk patients
32 3.25 All patients 7.2 Standard risk High risk 10E-7 Cut Point Analysis Hazard Ratios 10E-3 p-values MRD 10E-7 10E-3 MRD Optimal cut point for combined patients is ~0.01% p = 0.05 p = 0.05
33 B-LL End of Induction MRD Discordant Flow and HTS has intermediate outcome Similar result for Flow+/HTS- (N=17) Discordant = Concordant MRD- at lower HTS cutoff of 0.001%
34 SmMIPS Minimal error rate for via single molecule tagging Targets multiple genomic regions of interest Simple, scalable protocol Modular and cost-effective target enrichment Low sample input requirements
35 Abnormal myeloid blasts (%) N = 353 AML MRD NPM1 by NGS NPM1 mutant VAF (%) Zhou Y, et al (2017) submitted
36 Relapse free survival (%) AML MRD NPM1 by NGS Non-transplant N = 37 MRD MFC POS MRD NGS HI MRD LO/NEG Time (months) N = 5 N = 7 N = 25 Zhou Y, et al (2017) submitted
37 x The Cancer Genome Atlas Research Network (2013) NEJM 368:
38 Gene Capture Design AML MRD NGS Nucleotides sequenced (bp) 32 gene panel of AML mutations Coverage for ~85% of AML Sensitivity of 0.011% Number smmip probes Gene Capture Design Nucleotides sequenced (bp) Number smmip probes ABL1 Hotspot NT5C2 Hotspot ALK Hotspot PHF6 Full Gene BRAF Hotspot PIK3CA Hotspot CEBPA Full Gene PPM1D Full Gene DNMT3A Hotspot PTPN11 Full Gene EZH2 Full Gene RAD21 Full Gene FAM5C Full Gene RET Hotspot FLT3 Hotspot ROS1 Hotspot HNRNPK Full Gene RUNX1 Full Gene IDH1 Hotspot SMC1A Full Gene IDH2 Full Gene SMC3 Full Gene JAK2 Hotspot STAG2 Full Gene KIT Hotspot TET2 Full Gene KRAS Hotspot TP53 Full Gene NPM1 Hotspot 89 1 U2AF1 Hotspot NRAS Hotspot WT1 Full Gene Cell line variants Hotspot Total N/A Salipante, et al (2017) Haematologica 102(9):
39 AML MRD NGS Good correlation between multigene assay and standard NPM1 Salipante, et al (2017) Haematologica 102(9):
40 NGS Conclusions NGS is capable of MRD detection Can reproduce risk groups Sensitivity = NGS (10-6 ) > ASO-PCR > Flow Uses Standardize testing Simplify sample requirements Define MRD(-) low-risk group early Define MRD(+) high-risk group late (EOC)? better for targeted immunotherapy TAT of > 1 week currently
41 Subclonal CRLF2 CRLF2 deletion P2RY8-CRLF2 Harvey et al. (2016) submitted
42 Molecular Cytometry The ability to measure multiple molecular features at the single cell level for entire populations of cells
43 Tumor Heterogeneity Ma, et al (2015) Nature Communications DOI: /ncomms7604
44
45
46 Conclusions Diagnosis is immunophenotypic, classification is genotypic MRD detection provides important unique prognostic information in acute leukemia Is standard of care for B-ALL MRD by flow cytometry can be done reproducibly MRD by NGS is feasible for B-ALL, T-ALL and AML Single cell molecular methods are the next frontier
47 Acknowledgements Hematopathology Laboratory at UWMC Michael Borowitz MD PhD Entire COG ALL subcommittee Steven Hunger, Bill Carroll, Mignon Loh Adaptive Biotechnologies Harlan Robins (FHCRC)
Fundamentals of Next-Generation Sequencing: Technologies and Applications
Fundamentals of Next-Generation Sequencing: Technologies and Applications Society for Hematopathology European Association for Haematopathology 2017 Workshop Eric Duncavage, MD Washington University in
More informationFlow Cytometry in the Diagnosis of Hematopoietic Neoplasia. Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle
Flow Cytometry in the Diagnosis of Hematopoietic Neoplasia Brent Wood MD, PhD Professor, Laboratory Medicine University of Washington, Seattle 1 Flow Cytometer 2 The Power of Flow Cytometry Single cell
More informationHot Topic. Disclosures. None
Hot Topic Multiple Myeloma Testing at Mayo Medical Laboratories HOT TOPIC / 2017 MFMER 1 Our speaker for this program is Dragan Jevremovic, MD, PhD Assistant Professor, Division of Hematopathology at Mayo
More informationEnterprise Interest I am an employee of ThermoFisher Scientific.
Enterprise Interest I am an employee of ThermoFisher Scientific. Developing a multiplex next-generation sequencing assay to study highly clonal tumor samples Dumitru Brinza, Ph.D Clinical Next-Generation
More informationCongreso Nacional del Laboratorio Clínico 2016
Técnicas de alta sensibilidad en la detección de enfermedad mínima residual en Mieloma Múltiple J. Flores-Montero, MD, PhD Departamento de Medicina, Servicio Central de Citometría, Centro de Investigación
More informationUNDERSTANDING THE CLONOSEQ ASSAY
FOR HEALTHCARE PROVIDERS UNDERSTANDING THE CLONOSEQ ASSAY Clonality (ID) and Tracking (MRD) Reports clonoseq is an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies
More informationAccessible answers. Targeted sequencing: accelerating and amplifying answers for oncology research
Accessible answers Targeted sequencing: accelerating and amplifying answers for oncology research Help advance precision medicine Accelerate results with Ion Torrent NGS Life without cancer. This is our
More information2111: ALL Post-HCT. Add/ Remove/ Modify. Manual Section. Date. Description. Comprehensive Disease- Specific Manuals
2111: ALL Post-HCT The Acute Lymphoblastic Leukemia Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific post-hct data such as: planned treatments post-hct, the
More informationAnalytical verification methods for the Oncomine Lung cfdna Assay using the Ion S5 XL System
WHITE PAPER Oncomine Lung cfdna Assay and Ion S5 XL System Analytical verification methods for the Oncomine Lung cfdna Assay using the Ion S5 XL System Key highlights Investigate tumor heterogeneity and
More informationMinimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing
Minimal Residual Disease assessment in Multiple Myeloma by Next-Generation Sequencing Prof Hervé AVET-LOISEAU, : MD, PhD Institut Universitaire du Cancer Toulouse, France MRD Meta-Analysis in Myeloma Nikhil
More informationThese products are sold FOR RESEARCH USE ONLY; not for use in diagnostic procedures.
Minimal Residual Disease (MRD) testing by Next- Generation Sequencing (NGS) has become an important methodology demonstrating clear potential to optimize therapeutic management of lymphoproliferative diseases.
More informationTranslating Droplet Digital PCR into Clinical Use. Christopher Campbell West Midlands Regional Genetics Laboratory
Translating Droplet Digital PCR into Clinical Use Christopher Campbell West Midlands Regional Genetics Laboratory Introduction to digital PCR Applications in the West Midlands Regional Genetics Laboratory
More informationAssay Validation Services
Overview PierianDx s assay validation services bring clinical genomic tests to market more rapidly through experimental design, sample requirements, analytical pipeline optimization, and criteria tuning.
More informationHighly Sensitive, Multiplexed ctdna Mutation Detection on MassARRAY :
Highly Sensitive, Multiplexed ctdna Mutation Detection on MassARRAY : Lung & Colon Cancer Panel Pre-Launch & Data Sharing 栾晓辉, Ph.D. Senior Scientist, Application Development Agena Bioscience, Greater
More informationPMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA
PMDA Perspectives on Companion Diagnostics Development in Japan Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA 1 Disclaimer Content Slide The views and opinions expressed
More informationNext Generation Molecular Diagnostics in Scotland. Dr Mark Drummond Haematologist, Beatson Cancer Centre
Next Generation Molecular Diagnostics in Scotland Dr Mark Drummond Haematologist, Beatson Cancer Centre Outline Precision Medicine Regulatory and Funding background in Scotland (briefly) The Gap in the
More informationMutation analysis in cell-free DNA from cancer patients
Mutation analysis in cell-free DNA from cancer patients dr. Anneleen Beckers project manager & product manager at Biogazelle CRIG s digital PCR mini-symposium, May 15, 2018 2018 Biogazelle. All rights
More informationControlling Chaos in Oncology Testing
HORIZON DISCOVERY Controlling Chaos in Oncology Testing 16 th March 2016 Brian Burke PhD Disclaimer This Presentation does not constitute or form any part of an offer to sell, or invitation to purchase
More informationTowards detection of minimal residual disease in multiple myeloma through circulating tumour DNA sequence analysis
Towards detection of minimal residual disease in multiple myeloma through circulating tumour DNA sequence analysis Trevor Pugh, PhD, FACMG Princess Margaret Cancer Centre, University Health Network Dept.
More informationNUCLEOTIDE RESOLUTION STRUCTURAL VARIATION DETECTION USING NEXT- GENERATION WHOLE GENOME RESEQUENCING
NUCLEOTIDE RESOLUTION STRUCTURAL VARIATION DETECTION USING NEXT- GENERATION WHOLE GENOME RESEQUENCING Ken Chen, Ph.D. kchen@genome.wustl.edu The Genome Center, Washington University in St. Louis The path
More informationEmma Huxley. Principal Clinical Scientist West Midlands Regional Genetics Laboratory
Genetic Analysis Using a High Density SNP Array in Myelodysplastic Syndrome: Clinical Utility and Comparative Analysis Study Compared to Metaphase Chromosome Analysis. Emma Huxley Principal Clinical Scientist
More informationNGS-Based Clonality Testing Assessing Clonality Status, Somatic Hypermutation and Monitoring Minimum Residual Disease (MRD)
NGS-Based Clonality Testing Assessing Clonality Status, Somatic Hypermutation and Monitoring Minimum Residual Disease (MRD) Maria Arcila, M.D. Memorial Sloan Kettering Cancer Center Educational Goals Review
More informationSample to Insight. Dr. Bhagyashree S. Birla NGS Field Application Scientist
Dr. Bhagyashree S. Birla NGS Field Application Scientist bhagyashree.birla@qiagen.com NGS spans a broad range of applications DNA Applications Human ID Liquid biopsy Biomarker discovery Inherited and somatic
More informationAn Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case
Cartagenia Bench Lab Case Study An Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case At a Glance In this case study, you will learn: How the Molecular
More informationThe EORTC Molecular Screening programme SPECTA
The EORTC Molecular Screening programme SPECTA February 2016 Denis Lacombe, MD, MSc EORTC, Director General Brussels, Belgium The changing shape of clinical research Phase I RESOURCES Phase III The changing
More informationTargeted Sequencing of Leukemia-Associated Genes Using 454 Sequencing Systems
Sequencing Application Note March 2012 Targeted Sequencing of Leukemia-Associated Genes Using 454 Sequencing Systems GS GType TET2/CBL/KRAS and RUNX1 Primer Sets for the GS Junior and GS FLX Systems. Introduction
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationGenetic Units (GenUs) 2016 version: Instructions for use and table of GenU bands General instructions
Genetic Units (GenUs) 2016 version: Instructions for use and table of GenU bands The following notes are designed to ensure laboratories collect and report workload data consistently for UKGTN annual returns
More informationTECHNOLOGIES AVAILABLE FOR LICENSING AT UNIVERSITY OF DELHI
TECHNOLOGIES AVAILABLE FOR LICENSING AT UNIVERSITY OF DELHI Diagnostic Technologies: Letters of Intent are invited from Industrial organizations /companies for licensing and/or up scaling of following
More informationCelluvative. Cellular Therapies Redefined. A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow.
Cellular Therapies Redefined A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow. cell u va tive / sel-yoo-vā-tiv/ noun 1. a partnership between BloodCenter
More informationDesigning and Validating a Multicolor Flow Cytometry Assay. Brent Wood MD PhD Department of Laboratory Medicine University of Washington
Designing and Validating a Multicolor Flow Cytometry Assay Brent Wood MD PhD Department of Laboratory Medicine University of Washington Specimen Handling Sample Requirements 5 ml Peripheral blood (EDTA,
More informationAALL08B1: SPECIMEN TRANSMITTAL
INSTITUTIONAL REMINDERS: All specimens and this form MUST contain the COG number, patient s full name, date of birth and specimen type (BM or PB). COG ALL Reference Laboratories may be unable to analyze
More informationAgilent NGS Solutions : Addressing Today s Challenges
Agilent NGS Solutions : Addressing Today s Challenges Charmian Cher, Ph.D Director, Global Marketing Programs 1 10 years of Next-Gen Sequencing 2003 Completion of the Human Genome Project 2004 Pyrosequencing
More informationMolecular Diagnostics in Hematopathology. Madhuri Ramanathan Ph.D. Ridgewood, New Jersey ASCLS-NJ Spring Seminar April 14, 2016
Molecular Diagnostics in Hematopathology Madhuri Ramanathan Ph.D. Ridgewood, New Jersey ASCLS-NJ Spring Seminar April 14, 2016 Learning Objectives Explain the principles of Molecular Diagnostics Describe
More informationMutation analysis on difficult samples
Mutation analysis on difficult samples Manon M.H. Huibers, PhD Clinical Scientist in Molecular Pathology EBMWG meeting, Utrecht TOPIC II: New Techniques. Advances in diagnosis and therapeutic relevance,
More informationHaloPlex HS. Get to Know Your DNA. Every Single Fragment. Kevin Poon, Ph.D.
HaloPlex HS Get to Know Your DNA. Every Single Fragment. Kevin Poon, Ph.D. Sr. Global Product Manager Diagnostics & Genomics Group Agilent Technologies For Research Use Only. Not for Use in Diagnostic
More informationA new paradigm in testing for NSCLC-targeted therapies
A new paradigm in testing for NSCLC-targeted therapies Accelerate results, from sample to report, with the first IVD NGS-based test NEW Oncomine Dx Target Test The Ion Torrent Oncomine Dx Target Test is
More informationBrief Communication Diagnostic Genetics
Brief Communication Diagnostic Genetics Ann Lab Med 2017;37:331-335 https://doi.org/10.3343/alm.2017.37.4.331 ISSN 2234-3806 eissn 2234-3814 Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation
More informationQuality Control in Flow. Dr David Westerman Head of Haematopathology Peter MacCallum Cancer Centre
Quality Control in Flow Dr David Westerman Head of Haematopathology Peter MacCallum Cancer Centre Aims Quality Assurance Quality Control Literature In house competencies SHOT DATA 1996-2009 Ref: SHOT Annual
More informationNEXT-GENERATION CAR T-CELLS AGAINST CANCER. Gene-Edited Off-The-Shelf Immunotherapies
NEXT-GENERATION CAR T-CELLS AGAINST CANCER Gene-Edited Off-The-Shelf Immunotherapies Forward-looking Statements This presentation contains forward-looking statements that are based on our management s
More informationNEXTflex Myeloid Amplicon Panel (For Illumina Platforms) Catalog #NOVA (Kit contains 8 reactions) Bioo Scientific Corp V17.
NEXTflex Myeloid Amplicon Panel (For Illumina Platforms) Catalog #NOVA-4260-01 (Kit contains 8 reactions) Bioo Scientific Corp. 2017 V17.05 This product is for research use only. Not for use in diagnostic
More informationAn Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case
Bench Lab CASE STUDY An Automated Pipeline for NGS Testing and Reporting in a Commercial Molecular Pathology Lab: The Genoptix Case Authors: Matthew J. McGinniss 1, PhD FACMG, Executive Director, Molecular
More informationNEXT-GENERATION CAR T-CELLS AGAINST CANCER. Gene-Edited Off-The-Shelf Immunotherapies
NEXT-GENERATION CAR T-CELLS AGAINST CANCER Gene-Edited Off-The-Shelf Immunotherapies Forward-looking Statements This presentation contains forward-looking statements that are based on our management s
More informationIsoFluxTM. System. The next generation of CTC Analysis is here
IsoFluxTM System The next generation of CTC Analysis is here Product Overview IsoFlux System The next generation of circulating tumor cell analysis is here The IsoFlux System enriches intact rare cells
More informationA Crash Course in NGS for GI Pathologists. Sandra O Toole
A Crash Course in NGS for GI Pathologists Sandra O Toole The Sanger Technique First generation sequencing Uses dideoxynucleotides (dideoxyadenine, dideoxyguanine, etc) These are molecules that resemble
More informationOf children diagnosed with acute lymphoblastic leukemia
Journal of Pediatric Hematology/Oncology, Vol. 25, No. 2, February 2003 2003 Lippincott Williams & Wilkins, Inc. Original Article Real-Time Quantitative PCR: Standardized Detection of Minimal Residual
More informationDetection of Rare Variants in Degraded FFPE Samples Using the HaloPlex Target Enrichment System
Detection of Rare Variants in Degraded FFPE Samples Using the HaloPlex Target Enrichment System Application Note Author Linus Forsmark Henrik Johansson Agilent Technologies Inc. Santa Clara, CA USA Abstract
More informationAssociation for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology
Association for Molecular Pathology Promoting Clinical Practice, Basic Research, and Education in Molecular Pathology 9650 Rockville Pike, Bethesda, Maryland 20814 Tel: 301-634-7939 Fax: 301-634-7990 Email:
More informationSAMPLE. Nucleic Acid Amplification Assays for Molecular Hematopathology; Approved Guideline Second Edition
March 2012 Nucleic Acid Amplification Assays for Molecular Hematopathology; Approved Guideline Second Edition This guideline addresses the performance and application of assays for gene rearrangement and
More informationSureSelect XT HS. Target Enrichment
SureSelect XT HS Target Enrichment What Is It? SureSelect XT HS joins the SureSelect library preparation reagent family as Agilent s highest sensitivity hybrid capture-based library prep and target enrichment
More informationDRUGS LIFESPAN FOR PATIENTS DECADE TRIPLING THE IN THE LAST SURVIVAL IMPROVEMENT
10 40 % 3 IMPROVEMENT DRUGS IN THE LAST DECADE IN 5 YEAR SURVIVAL X TRIPLING THE LIFESPAN FOR PATIENTS 4 Drugs Approved in 2015! FDA APPROVALS IN 2015 Drug FDA Approval Panobinostat (Farydak ) February
More informationInterpretation of karyotyping using mitogens vs FISH vs SNP-based array in CLL. Arnon Kater Dept of Hematology AMC Amsterdam
Interpretation of karyotyping using mitogens vs FISH vs SNP-based array in CLL Arnon Kater Dept of Hematology AMC Amsterdam 1 Introduction Accepted diagnostic workup CLL prior to treatment FISH 13q, tris
More informationImplementation of Ion AmpliSeq in molecular diagnostics
Implementation of Ion AmpliSeq in molecular diagnostics The Rotterdam Experience Ronald van Marion Deelnemersbijeenkomst SKML sectie Pathologie Amersfoort, 26 mei 2016 Molecular Diagnostics in Rotterdam
More informationSUPPLEMENTARY INFORMATION
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Wataru Sakai, Elizabeth M. Swisher, Beth Y. Karlan, Mukesh K. Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas,
More informationEvaluation of Restriction Enzymes for the Analysis of Circulating Free DNA by Droplet Digital PCR
Evaluation of Restriction Enzymes for the Analysis of Circulating Free DNA by Droplet Digital PCR Amanda Weaver Cancer Genomics Consortium 2017 Summer Meeting August 7, 2017 Acknowledgements Everyone at
More informationIn Vitro Companion Diagnostic Devices
4 th of Joint Conference of Taiwan and Japan on Medical products regulation In Vitro Companion Diagnostic Devices 2016/12/7 Aoyagi Yumiko Ministry of Health, Labour and Welfare Medical Device Evaluation
More informationCAPTURE-BASED APPROACH FOR COMPREHENSIVE DETECTION OF IMPORTANT ALTERATIONS
CAPTURE-BASE APPROACH FOR COMPREHENSIVE ETECTION OF IMPORTANT ALTERATIONS SEQUENCE MUTATIONS MICROSATELLITE INSTABILITY AMPLIFICATIONS GENOMIC REARRANGEMENTS For Research Use Only. Not for iagnostic Purposes.
More informationCASE-STUDY- VALIDATION of PCR based methodology. Beata Surmacz-Cordle Senior Analytical Development Scientist
CASE-STUDY- VALIDATION of PCR based methodology Beata Surmacz-Cordle Senior Analytical Development Scientist UK RMP Pluripotent Stem Cell Platform Validation Workshop 2 nd June 2016 RT-qPCR assay for detection
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1: Vector maps of TRMPV and TRMPVIR variants. Many derivatives of TRMPV have been generated and tested. Unless otherwise noted, experiments in this paper use
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationUAMS ADVANCED DIAGNOSTICS FOR ADVANCING CURE
UAMS ADVANCED DIAGNOSTICS FOR ADVANCING CURE advanced diagnostics for advancing cure Multiple myeloma (myeloma) is a complex cancer that can be diffcult to diagnose and challenging to treat. Every case
More informationPerformance of the Newly Developed Non-Invasive Prenatal Multi- Gene Sequencing Screen
1 // Performance of the Newly Developed Non-Invasive Prenatal Multi- Gene Sequencing Screen ABSTRACT Here we describe the analytical performance of the newly developed non-invasive prenatal multi-gene
More informationStandardization of Minimal Residual Disease Testing in Multiple Myeloma
Standardization of Minimal Residual Disease Testing in Multiple Myeloma Linda B. Baughn 1 and Michael A. Linden 2 * Multiple myeloma (MM) 3 is an incurable neoplasm of the bone marrow characterized by
More informationBrian GM Durie. Black Swan Research Initiative (BSRI) Purpose
Black Swan Research Initiative Brian GM Durie Saturday August 22, 2015 1 Black Swan Research Initiative (BSRI) Purpose The Black Swan Research Initiative (BSRI) is a global collaborative approach Which
More informationCLEARLLAB LS LYMPHOID SCREEN REAGENT
CLEARLLAB LS LYMPHOID SCREEN REAGENT CE MARKED ANTIBODY COMBINATION FOR LEUKEMIA / LYMPHOMA ANALYSIS Because Your Patient is Her Everything BECAUSE YOUR PATIENT IS HER EVERYTHING ClearLLab LS Lymphoid
More informationCorporate Overview. December Erik Holmlin President & CEO
Corporate Overview December 2018 Erik Holmlin President & CEO Forward-Looking Statements This presentation contains forward-looking statements. Forward-looking statements describe future expectations,
More informationPersonalized CAR-T Immunotherapy Platform
GLP, GMP, and CLIA-Certified Lab Personalized CAR-T Immunotherapy Platform Accelerate your cancer research and drug discovery Platform Overview 1500 Existing Hybridomas and Antibody Engineering Custom
More informationTHE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org
THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA themmrf.org ABOUT THE MULTIPLE MYELOMA RESEARCH FOUNDATION The Multiple Myeloma Research Foundation (MMRF) was established in 1998 by identical twin sisters
More informationParis Seminar for Patients & Caregivers: BSRI 2017 On the Path to a Cure. Brian GM Durie Saturday, June 10, 2017
Paris Seminar for Patients & Caregivers: BSRI 2017 On the Path to a Cure Brian GM Durie Saturday, June 10, 2017 1 Black Swan: on the way to a cure Sustained low level disease Favorable immune signature
More informationDURACLONE IM ACCELERATE YOUR PACE IN IMMUNE SYSTEM RESEARCH. For Reseach Use Only - Not for use in Diagnostic procedures
DURACLONE IM ACCELERATE YOUR PACE IN IMMUNE SYSTEM RESEARCH Your clinical research trial companion For Reseach Use Only - Not for use in Diagnostic procedures ACCELERATE YOUR PACE IN IMMUNE SYSTEM RESEARCH
More informationMM12-A ISBN Volume 26 Number 20 ISSN Diagnostic Nucleic Acid Microarrays; Approved Guideline
ISBN 1-56238-608-5 Number 20 ISSN 0273-3099 Diagnostic Nucleic Acid Microarrays; Approved Guideline Joseph L. Hackett, PhD Kellie J. Archer, PhD Adolfas K. Gaigalas, PhD Carleton T. Garrett, MD, PhD Loren
More informationMaximizing your NGS sequencing with IDT. Adam Chernick, PhD Field Applications Manager, Functional Genomics
Maximizing your NGS sequencing with IDT Adam Chernick, PhD Field Applications Manager, Functional Genomics 1 Contents Expanding our NGS portfolio what s next? xgen technology and Lockdown probe advantages
More informationImmunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A.
Immunophenotyping of Peripheral Blood and Bone Marrow Cells by Flow Cytometry *Akanni EO and # Palini A. * Department of Haematology & Blood Transfusion,College of Health Science, Ladoke Akintola University
More informationTechnical Information. Intended Use. Contraindications. Special Conditions for Use. Summary and Explanation
Adaptive Biotechnologies Corporation 1551 Eastlake Ave E, Suite 200, Seattle, WA 98102 Phone: (855) 466-8667 Intended Use The clonoseq Assay is an in vitro diagnostic that uses multiplex polymerase chain
More informationIntended Use. Contraindications. Special Conditions for Use. Summary and Explanation
clonoseq Assay Adaptive Biotechnologies Corporation 1551 Eastlake Ave E, Suite 200, Seattle, WA 98102 Phone: (855) 466-8667 Intended Use The clonoseq Assay is an in vitro diagnostic that uses multiplex
More informationApplication of High Resolution Melting Analysis in Haematological Diagnosis
Application of High Resolution Melting Analysis in Haematological Diagnosis Dr Jason C C So Clinical Associate Professor Department of Pathology The University of Hong Kong Haematology and Genetics Blood
More informationManaging Specimen Stability for Robust Flow Cytometric Clinical Biomarker Assays
Managing Specimen Stability for Robust Flow Cytometric Clinical Biomarker Assays Dianna Wu, Richard Wnek Molecular Biomarkers & Diagnostics Merck Co., Inc 2014 AAPS Annual Meeting San Diego, CA (Fluorescent
More informationIncorporating New TB Diagnostics into RePORT
Incorporating New TB Diagnostics into RePORT Susan Dorman Johns Hopkins University School of Medicine REPORT MEETING, DURBAN, JULY 2016 MACS designed to: 1. Elucidate the natural history of the infection
More informationUse of Biomarkers in Drug Development. Janet Woodcock M.D. Director, CDER, FDA
Use of Biomarkers in Drug Development Janet Woodcock M.D. Director, CDER, FDA Biomarkers: Extremely Critical to Drug Development Availability of a pharmacodynamic response marker (e.g., viral load) truly
More informationSupplemental Table S1. RT-PCR primers used in this study
Supplemental Table S1. RT-PCR primers used in this study -----------------------------------------------------------------------------------------------------------------------------------------------
More informationTarget Enrichment Strategies for Next Generation Sequencing
Target Enrichment Strategies for Next Generation Sequencing Anuj Gupta, PhD Agilent Technologies, New Delhi Genotypic Conference, Sept 2014 NGS Timeline Information burst Nearly 30,000 human genomes sequenced
More informationMid-West Biopharmaceutical Workshop May Jonathan Denne a, Gene Pennello b, Luping Zhao a, Shao-Chun Chang a & Sandra Althouse c
Identifying a Subpopulation for a Tailored Therapy: Bridging Clinical Efficacy From a Laboratory-Developed Assay to a Validated In Vitro Diagnostic Test Kit Published in: Statistics in Biopharmaceutical
More informationClinical Molecular Biology A Danish Perspective
Clinical Molecular Biology A Danish Perspective Niels Pallisgaard Molecular biologist Clinical Biochemistry, Vejle Sygehus niels.pallisgaard@slb.regionsyddanmark.dk Here s my DNA sequence The Epidermal
More informationGenes deleted by P335 MLPA kit ** EBF1 ex16, IKZF1, ALL97. CDKN2A, add(12)(p12),add(14)(q32),del(17)(p12), CDKN2B, PAX5,
Supplementary Table 1 Genetics and FISH results for EBF1-PDGFRB positive patients Patient no. EBF1- PDGFRB fusion detected by RT-PCR 5q33 deletion detected by SNP6.0 Unique ID Trial Karyotype PDGFRB FISH
More informationImplement New Technologies in NBS: Next Generation Sequencing in NBS for Cystic Fibrosis
Implement New Technologies in NBS: Next Generation Sequencing in NBS for Cystic Fibrosis Mei Baker, MD, FACMG Co-Director, Newborn Laboratory at WSLH Professor, Department of Pediatrics University of Wisconsin
More informationFluorescence in situ hybridization (FISH) Testing in Multiple Myeloma
Fluorescence in situ hybridization (FISH) Testing in Multiple Myeloma William Bellamy, Ph.D., HCLD (ABB), CC (ABB) Arkansas Clinical Laboratory Management Association/ American Society for Clinical Lab
More informationFor knockdown of individual genes, the following TRC library clones were used: Gene Species Library TRC number Designation in manuscript
Supplemental Methods shrna constructs for validation experiments For knockdown of MLL-AF9, a custom shrna with the following stem sequence directed against the fusion breakpoint (underlined) was designed
More informationCHARTING THE COURSE FOR PRECISION MEDICINE
A Friends of Cancer Research White Paper CHARTING THE COURSE FOR PRECISION MEDICINE ADOPTING CONSENSUS ANALYTICAL STANDARDS AND STREAMLINING APPROVAL PATHWAYS FOR POST-MARKET MODIFICATIONS FOR NGS TESTS
More informationIs monitoring of chimerism predicting relapse and allowing preemptive immunotherapy? Fabio Ciceri, MD San Raffaele Scientific Institute Milano, Italy
Is monitoring of chimerism predicting relapse and allowing preemptive immunotherapy? Fabio Ciceri, MD San Raffaele Scientific Institute Milano, Italy Fabio Ciceri, MD San Raffaele Scientific Institute,
More informationFlow Cytometric Preparation of CD34 + CD90 + Hematopoietic Stem Cells for Transplantation
Flow Cytometric Preparation of CD34 + CD9 + Hematopoietic Stem Cells for Transplantation B R YA N F OX S TA N F O R D L A B O R AT O R Y F O R C ELL & G ENE M E D I C I N E ISCT Regional Meeting Memphis,TN
More informationVALIDATION OF HLA TYPING BY NGS
VALIDATION OF HLA TYPING BY NGS Eric T. Weimer, Ph.D., D(ABMLI) Assistant Professor, Pathology and Laboratory Medicine Associate Director, Clinical Flow Cytometry, HLA, and Immunology Laboratories CONFLICT
More informationAVANÇOS NO DIAGNÓSTICO E CLASSIFICAÇÃO IMUNOFENOTIPICA DE LEUCEMIAS LINFOCITICAS CRÓNICAS B
AVANÇOS NO DIAGNÓSTICO E CLASSIFICAÇÃO IMUNOFENOTIPICA DE LEUCEMIAS LINFOCITICAS CRÓNICAS B CANCER RESEARCH CENTER IBSAL-UNIVERSITY OF SALAMANCA/CSIC HEMO 2016 Congreso Brasileiro de Hematologia, Hemoterapia
More informationMultiplex Assay Design
Multiplex Assay Design Geeta Bhat, Luminex Molecular Diagnostics; Toronto. APHL/CDC Newborn Screening Molecular Workshop, CDC, Atlanta, GA June 28-30, 2011 Luminex Multiplexed Solutions. For Life. Luminex
More informationTITLE: Genomewide Screen for Synthetic Lethal Interactions with Mutant KRAS in Lung Cancer
Award Number: W81XWH-16-1-0287 TITLE: Genomewide Screen for Synthetic Lethal Interactions with Mutant KRAS in Lung Cancer PRINCIPAL INVESTIGATOR: Yin-Yuan Mo CONTRACTING ORGANIZATION: University of Mississippi
More informationDeborah Dunsire, M.D. President and CEO. Annual Meeting of Shareholders Cambridge, MA May 4, 2006
Deborah Dunsire, M.D. President and CEO Annual Meeting of Shareholders Cambridge, MA May 4, 2006 2006 Millennium 2006 Pharmaceuticals Millennium Inc. Pharmaceuticals, Inc. Agenda 2005 Key Accomplishments
More informationDigital DNA/RNA sequencing enables highly accurate and sensitive biomarker detection and quantification
Digital DNA/RNA sequencing enables highly accurate and sensitive biomarker detection and quantification Erwin Chen ( 陳立德 ) Technical Product Specialist QIAGEN Taiwan Precision medicine: Right drug, right
More informationNGS immunogenetic analysis in vitro: clonality feasibility study
NGS immunogenetic analysis in vitro: clonality feasibility study ERIC EuroClonality-NGS 1-day workshop Rotterdam, NL, November 24, 2017 Anton W. Langerak, Laboratory for Medical Immunology, Dept. Immunology
More informationTargeted Sequencing in the NBS Laboratory
Targeted Sequencing in the NBS Laboratory Christopher Greene, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Gene Sequencing in Public Health Newborn Screening February
More informationIntroducing combined CGH and SNP arrays for cancer characterisation and a unique next-generation sequencing service. Dr. Ruth Burton Product Manager
Introducing combined CGH and SNP arrays for cancer characterisation and a unique next-generation sequencing service Dr. Ruth Burton Product Manager Today s agenda Introduction CytoSure arrays and analysis
More informationHector R. Wong, MD Division of Critical Care Medicine Cincinnati Children s Hospital Medical Center Cincinnati Children s Research Foundation
Mechanisms of Sepsis Exploiting Pathogenic Genes Hector R. Wong, MD Division of Critical Care Medicine Cincinnati Children s Hospital Medical Center Cincinnati Children s Research Foundation Critical Care
More information